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Sumnlal'y 
The regions of antigenic variation in influenza hemagglutinin (HA) are located on surface-accessible 
regions in the three-dimensional structure of the HA1 monomer. The aim of this study was 
to establish whether a novel variant virus, IMUT4,  in which we had mutated specific amino 
acid residues (HA1 63, 144, 158, and 193) in these regions, previously shown to be immunodominant 
for CBA/Ca mice, would either (a) establish holes in the antibody (ab) repertoire or (b) preclude 
further antigenic variation in IMUT4. CBA/Ca mice were able to mount a neutralizing ab response 
to IMUT4 infection and molecular recognition sites were established by sequencing of the HA 
genes of monoclonal antibody (mAb)-selected laboratory variants of wild-type X31 virus (HA1 
131, 145, 155, and 196). However, each of these mAbs failed to select further antigenic variants 
of IMUT4,  in ovo, but rather a receptor binding mutant (HA1 190 Glu --* Asp;  226 Leu --- 
Gln) that was still  recognized by the selecting mAb, specific for HA1  155 of X31 virus. The 
facility for antigenic variation in influenza would appear to be compromised, therefore, by targeted 
mutation of immunodominant sites,  as initially proposed by S. Fazekas  de St.  Groth (Fazekas 
de St. Groth, S. 1977. Antigenic, adaptive and adsorptive variants of the influenza haemagglutinin. 
In Topics in Infectious Diseases. Vol. 3. R.G. Laver, H. Bachmayer, and R. Weil, editors. Springer- 
Verlag,  Vienna. 25-48.).  It is interesting to note that recent isolates  of the H3 subtype, (e.g., 
A/Beijing/92)  obtained between 1991 and 1993,  contain the same substitutions  at HA1  190 
and 226,  which may indicate similar constraints to immune evasion  and the relevance of our 
findings to antigenic variation in the human population. 
E 
nvelope glycoproteins of RNA viruses such as the hemag- 
glutinin (HA) of influenza undergo frequent antigenic 
change as a result of immune pressure from the host neu- 
tralizing Ab response acting in concert with the error-prone 
virus polymerase. This presents a formidable problem to suc- 
cessful vaccine design. A  desirable goal would be to elicit 
heterotypic immunity to more conserved regions of the mol- 
ecule, proximal to the receptor binding site. Sequence anal- 
yses of influenza A HA genes from natural and laboratory 
variant viruses have identified amino acid residues that are 
featured in antigenic drift and thereby define the recognition 
sites for neutralizing Ab (1-6). In the three-dimensional struc- 
ture of the bromelain-cleaved HA trimer (7,  8),  antigenic 
drift residues are clustered in five surface accessible regions 
on the membrane distal ectodomain of the HA1 subunit (an- 
tigenic sites A, B, C, D, and E) adjacent to conserved residues 
that constitute the receptor binding site (9). 
We have found that,  after natural infection of CBA/Ca 
mice (H-2  k) with X31 virus (H3N2 subtype), neutralizing 
Abs recognized a limited number of antigenic sites as deduced 
from sequence analysis of X31 laboratory variants selected, 
in ovo with mAb (10).  Such immunodominance after in- 
fection of an inbred mouse strain provides an opportunity 
to investigate "plasticity" of the immune repertoire to anti- 
genic variation. We have produced a novel variant virus of 
X31 (IMUT4) by sequential selection, in ovo with neutralizing 
mAbs representative of the previously defined Ab binding 
sites for CBA/Ca mice (HA1 63 Asp -* Asn; HA1 144 Gly 
--~ Asp; HA1  158 Gly --~ Glu; and HA1  165 Asn --~ Set). 
We demonstrate here that CBA/Ca mice are able to mount 
a neutralizing Ab response after infection with IMUT4 and, 
that therefore, there were no holes established in the immune 
repertoire. The molecular recognition specificity of the Ab 
response was determined by sequencing of the HA genes of 
antigenic variants of X31 virus selected in ovo by representa- 
tive mAbs. However, these same mAbs were unable to select 
further antigenic variants of IMUT4 virus. After repeated 
rounds of selection with  subneutralizing levels of a mAb 
specific for HA1 155 (of X31 virus), we obtained a receptor- 
binding variant of IMUT4 with substitutions in conserved 
residues that constitute part of the receptor-binding pocket, 
HA1  190 and 226.  A limited number of mutations in im- 
munodominant sites can therefore provide constraints to fur- 
ther antigenic change, be of some relevance to vaccine de- 
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in immune evasion. 
Table  1.  Frequency  and Specificity of Neutralizing mAb established 
from Individual CBA/Ca Donors 
Materials and Methods 
Mica  CBA/Ca mice were bred under specific  pathogen-flee con- 
ditions at the National Institute for Medical Research, and were 
infected intranasally with virus at 3-4 mo of age. 
Viruses.  All influenza viruses were grown in the allantoic cavity 
of 10-d-old embryonated eggs. The X31 virus is a recombinant 
between A/Aichi/2/68 and A/PR/8/34 which expresses surface 
glycoproteins of the H3N2 subtype and PR8 internal  proteins. 
Laboratory-selected  mutants were obtained by mixing equal volumes 
of allantoic fluid from X31-infected embryonated eggs and ascitic 
fluid containing anti-HA mAb. The virus-mAb mixture was in- 
cubated at ambient temperature for 30 min and then used to in- 
oculate embryonated eggs. Alternatively, for IMUT4, virus was 
incubated with serial dilutions of mAb and, exposed to sequential 
selection (x3) so as to isolate an escape mutant. The variants ob- 
tained were cloned in ovo by limiting dilution. The virus was purified 
from ,o2.5 liters of allantoic fluid by precipitation with polyeth- 
ylene glycol (5%) followed by sucrose gradient (15-40% [wt/vol]) 
centrifugation. 
Production ofmAh  CBA/Ca mice were infected  intranasally  with 
106 PFU (50/~1 allantoic fluid) of IMUT4 virus and boosted 8 wk 
later with 2  x  10  s PFU administered by intraperitoneal injection. 
3 d after boosting, splenic lymphocytes from individual donors were 
used for the production of mAb. Hybridomas were screened for 
anti-HA activity by hemagglutination  inhibition (HI) assays using 
turkey erythrocytes. 
Nucleotide Sequence Analyses of the HA Genes of Laboratory Mu- 
tant Viruses.  RNA was phenol extracted from purified virus sus- 
pensions followed by an ether wash. Nucleotide  sequences were 
determined using the dideoxynucleotide  chain terminating method, 
as described elsewhere (11). 
Results 
Immunodominant  Antigenic  Sites.  We have shown previ- 
ously (10) that, after intranasal infection with X31 virus, the 
neutralizing Ab response of CBA/Ca mice is focused on a 
few immunodominant regions of the HA1 subunit. This was 
deduced from sequence analyses of laboratory variant viruses 
selected with mAbs that had been established from a panel 
of individual donor mice. The frequency and specificity of 
CBA/Ca-derived mAbs are summarized in Table 1, showing 
that the major neutralizing epitopes are centered on HA1 
158 Gly --~ Glu (60%) and HA1 63 Asp ~  Ash (17%). Sev- 
eral novel laboratory mutants were also selected with single 
amino acid substitutions that had not been reported previ- 
ously for H3 subtype viruses (HA1 62 Ile --* Arg; HA1 165 
Asn --- Ser;  and HA1  273 Pro --~ Leu). 
Sequential Selection of Variant Virus, IMUT4.  We wished 
to determine whether each of the antigenic sites  that had 
been featured in the CBA/Ca repertoire (Table  1) could be 
mutated (by mAb selection) so as to produce a laboratory 
variant that was no longer recognized by this particular mouse 
strain.  The strategy for sequential Ab selection, in ovo, is 
summarized in Fig.  1.  It should be emphasized that it was 
essential,  at each selection step, to establish that antigenically 
Antigenic  specificity  Frequency 
HA1  62  Ile  -~ Arg*  1/40# 
HA1  63  Asp -+Asn  7/40 
HA1  129  Gly -~ Trp  2/40 
HA  144  Gly--~ Asp  2/40 
HA1  158  Gly -~ Glu  24/40 
HA1  165  Asn ~  Set  1/40 
HA1  188  Asn -~ Asp  2/40 
HA1  273  Pro  ~  Leu  1/40 
* Antigenic specificity  was deduced from the single amino acid substitu- 
tions in laboratory  mutants of X31 virus, selected  in ovo with the cor- 
responding mAb. 
# A total of 40 mAbs were established from five CBA/Ca donors after 
intranasal infection  with X31 virus. 
distinct regions of HA1 were not perturbed so as to preclude 
further mAb selection. After each mAb treatment, escape 
mutants were cloned, their HA genes sequenced, and their 
reactivity for unrelated mAb specificities determined by HI 
assays. 
IMUT2:  HA1  158  Gly  --*  Glu;  63 Asp  --* Asn.  The 
starting point for selection was a laboratory variant of X31 
virus, HA1  158 Gly -~ Glu, since this was the most anti- 
genic and frequently selected escape mutant. After further 
mAb selection, we confirmed, by cDNA sequencing, that 
IMUT-2 contained the relevant substitution HA1  63 Asp 
Ash. This introduced an additional Noglycosylation site 
(Asn63 Cys64  Thr65) and the presence of an oligosaccharide 
side chain abrogated recognition by mAbs specific for HA1 
62 (antigenic site C) or HA1 273 (antigenic site E), as shown 
in HI assays (data not shown). Therefore, these mAbs were 
not used for any further selection. 
IMUT3: HA1 158 Gly --; Glu; 63 Asp -~ Asn; 144 Gly --~ 
Asp.  A mAb specific for HA1 144 (Gly --* Asp) was shown 
to recognize IMUT2 in HI assays and was able to select an 
escape  mutant with the corresponding substitution. 
IMUT4: HAl  158 Gly -* Glu; 63 Asp --~ Asn; 144 Gly 
--* Asp; 193 Ser --~ Arg.  A mAb specific for HA1 165 (Asn 
-~ Set) had previously selected (10) a laboratory mutant of 
X31 virus with the loss of an N-glycosylation site (Asn16s 
Va1166 Thr167). This  same  Ab  now  selected  a  variant  of 
IMUT3 with an alternative substitution, HA1 193 Set ~  Arg. 
Neutralizing mAb Elicited by IMUT4 Infection.  We wished 
to determine whether CBA/Ca mice were able to mount a 
protective immune response to infectious intranasal challenge 
with IMUT4. Despite the pronounced virulence (LD50 <  5 
￿  106 PFU) of both wild-type X31  and IMUT4 viruses, 
mAbs were established from two CBA/Ca donors that re- 
ceived a  minimal  infectious challenge with  IMUT4  (106 
PFU). A predominance of the IgG2a isotype was consistent 
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144 Gly~Asp;  193 Ser~Arg 
Figure 1.  Sequential  mAb selection  of  laboratory  variants 
of X13 virus, indicating the specificity  of the selecting  anti- 
body and mutations in the corresponding  laboratory  variants. 
with recruitment of a Thl type T  cell response to virus in- 
fection. 
Nucleotide  Sequence  Analysis  of Mutant  HAs.  The neu- 
tralizing mAbs generated from IMUT4-infected mice were 
used to select variants of the parental X31 virus in the first 
instance. 
A definitive assignment of antigenic specificities was pos- 
sible for representative mAbs from donors F1 and F3 by se- 
quencing of laboratory variants. Table 2 summarizes the single 
amino acid substitutions in X31 variant viruses VFX-11 (HA1 
196 Val --~ Ile) VFX-13 (HA1 131 Thr -~ Ile), VFX-14 (HA1 
145 Ser --~ Asn), VFX-32 (HA1 196 Val ~  Ile), and VFX-33 
(HA1 155 Thr --" Ile). It should be emphasized that between 
15 and 20 mAbs were established from each donor and were 
representative of these specificities  in binding assays. 
It is of interest that (apart from HA1 145) these changes 
have not been reported previously for laboratory variants of 
the H3 subtype. And although the HA1 155 Thr -~ Ile change 
has occurred in recent H3 natural isolates (see below), HA1 
196 and HA1  131  are conserved residues. 
Table  2.  Amino Acid Substitutions in Laboratory Variants of X31 
Virus, Selected with mAbs from Individual CBA/Ca  Donors after 
Infection with IMUT4 
Amino  acid 
mAb  Isotype  Laboratory variant  change (HA1) 
FO1-11  IgG2a  VFX-11  196 Val  "-~ Ile* 
FO1-13  IgG2a  VFX-13  131 Thr ~  Ile 
FO1-14  IgG2a  VFX-14  145 Ser  --~ Asn 
FO3-32  IgG2a  VFX-32  196 Val  "" lie 
FO3-33  IgG2a  VFX-33  155 Thr ~  lie 
* Single amino acid substitutions in HA1 deduced by sequencing HA 
genes of laboratory variants. 
We failed, however, to obtain variants of the immunizing 
IMUT4 virus using the same mAbs and a variety of selec- 
tion procedures, including single round selection in cultured 
MDCK cells. After repeated in ovo selection (three rounds 
at subneutralizing levels) with mAb FO3-33 (specific for HA1 
155 of X31 virus) a resistant mutant IMUT4-V33 was ob- 
tained that differed from IMUT4 by two further changes: 
HA1  190 Glu --- Asp,  and 226 Leu --- Gln (Table  3). 
IMUT4-V33  Is a Receptor-binding  Mutant.  Glu 190 and 
Leu 226 are conserved residues in H3 subtype viruses and 
are implicated in receptor binding, (9, 12, 13). Since we had 
screened the mutant viruses by HI assay, this would also de- 
tect viruses with increased or altered receptor affinity. There- 
fore, we examined the recognition specificity of mAb VFX-33 
(HA1  155) for X31 or IMUT4-V33 by ELISA and found 
that it reacted equally to wild type and mutant virus (data 
not shown). IMUT4-V33 is therefore not an antigenic variant. 
Changes in Receptor-binding Specificity of  Mutant HAs.  The 
drift substitution, HA1 155 Thr --~ Tyr, in H3 subtype iso- 
Table 3.  Amino Acid Substitutions in a Laboratory Variant of 
IMUT4  Virus, Selected with  mAb Specific for HAl  155 
(Thr --~ lie), F03-33 
Amino acid 
mAb  Laboratory variant  change  (HA1) 
FO3-33"  IMUT4-V33  190 Glu "~ Asp 
226 Leu "-" Gin 
63 Asp ~  Asn* 
144 Gly "" Asp# 
158 Gly ~  Glu* 
193 Set  "-~ Arg* 
* The specificity  of the selecting mAb for HA1 155 (Thr ~  lie) was 
determined by sequencing the HA gene of a laboratory  variant of X31 
virus (see Table 2). 
# Amino acid substitutions present in the "parental" IMUT4 virus. 
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and Inhibition of Hemagglutination by Horse Serum 
HAU  HI 
Virus  Turkey RBC  Horse RBC  Turkey RBC;  Horse serum 
X31  1,204  <2  10,240" 
VFX-33  1,024  1,024  10,240 
IMUT4-V33  1,024  <2  <20 
X31-HS  1,024  <2  <20 
* The titer for hemagglutinin inhibition by serial dilution of horse serum. 
lates has been implicated in conferring agglutinin activity for 
RBC that contain N-glycolyl neuraminic acid residues (such 
as horse RBC) whereas A/Aichi/2/68 exhibits strict specificity 
for N-acetyl neuraminic acid (14). It was of interest, there- 
fore, to determine the agglutinin specificity of VFX-33 (HA1 
155 Thr -'* lie). Table 4 shows that, in contrast to wild-type 
X31 virus, VFX-33 agglutinates turkey and horse RBC equally 
well, illustrating the importance of HA1  155  in receptor- 
binding specificity. 
The HA receptor of human H3 isolates has specificity for 
the  anomeric linkage of sialic  acid  and preferentially ag- 
glutinates RBC containing sialyl cr2,6 galactose residues.  A 
receptor-binding variant X31-HS (HA1 226 Leu --- Gln) had 
been selected previously for its resistance to hemagglutinin 
inhibition by horse serum ot2-macroglobulin,  and had in- 
creased affinity for the sialyl ot2,3 anomeric linkage (12). In 
Table 4 we have compared the susceptibility of X31, X31- 
HS, and IMUT4-V33 to hemagglutinin inhibition by horse 
serum. Both mutant viruses have a common substitution (HA1 
226 Leu ~  Gln),  and are equally resistant to horse serum 
inhibition, thereby confirming their altered receptor-binding 
specificity for sialic acid. 
Discussion 
This study has demonstrated that the introduction of key 
mutations in the globular head region of the HA1 subunit 
provides structural constraints on further antigenic change 
in influenza under immune pressure of neutralizing mAb. 
Even so, such constraints can be countered (by the virus) by 
changes in  virus  receptor specificity (or  affinity),  thereby 
providing an additional mechanism of immune evasion. 
Our initial aim was to establish whether introduction of 
predetermined mutations  in  antigenic regions of the HA 
molecule, previously shown to be immunodominant in the 
neutralizing Ab response of CBA/Ca mice to X31 virus in- 
fection, would either establish holes in the repertoire, or con- 
versely, produce a variant virus that was no longer able to 
mutate (in vitro) under selective pressure of neutralizing mAb. 
To this end, we produced a novel laboratory variant of X31 
(IMUT4:HA1  63 Asp --* Asn;  144 Gly --* Asp;  158 Gly 
-~ Glu; and 193 Set --- Arg) by sequential antibody selec- 
tion, in ovo. After infectious challenge with IMUT4, it was 
possible  to obtain neutralizing mAbs from CBA/Ca mice 
and their recognition specificity determined by the selection 
of laboratory variants and sequencing of their HA genes. 
Therefore,  there  was  no  hole  in  the  host-protective  Ab 
repertoire. 
All of the mAbs recognized the wild-type X31 virus and 
selected variants with single substitutions at HA1  131 Val 
-~ Ile, HA1  155 Thr --- Ile, HA1  196 Val --~ Ile, or HA1 
145 Set -* Asn. Most of these are novel changes that have 
not been reported previously for laboratory variants and in- 
clude changes at conserved positions (Val 131 or Val 196) that 
have featured in antigenic drift. Despite repeated attempts, 
we failed to select laboratory variants of IMUT4 using the 
same mAbs and selection protocol. Finally, after three selec- 
tion cycles with mAb FO3-33 (specific for HA1 155), a labo- 
ratory variant of IMUT4 was obtained with two further amino 
acid substitutions at HA1 190 Glu ~  Asp, 226 Leu ~  Gln. 
These are conserved residues that form an integral part of 
the receptor-binding pocket (9,  and Fig.  2). 
Sequence analyses of natural variants of the H3 subtype 
isolated in the past 20 yr indicate that more than 35 drift 
substitutions have occurred within antigenically significant 
regions of HA1.  (3, 8).  It is surprising, therefore, that the 
introduction of such a limited number of substitutions in 
IMUT4 impose such constraints on further antigenic change. 
Although IMUT4 elicits neutralizing Ab responses after nat- 
ural infection, and specificity is readily determined by mAb 
selection of X31 variant viruses, we have failed to select fur- 
ther antigenic variants of IMUT4. 
Given the extensive correlates that are available for anti- 
genic  variability,  receptor-binding  specificity,  and  three- 
dimensional structure of the HA of X31 virus, we are able 
to interpret our findings at the molecular level. In the three- 
dimensional structure of HA complexed with sialyl lactose 
(9), the receptor-binding site is a cleft at the membrane distal 
tip surrounded by variable residues that have featured in an- 
tigenic drift. Fig. 2 is a schematic representation of the receptor- 
binding site occupied by sialic acid (as depicted in reference 
9),  and indicates its possible hydrogen-bonded contacts to 
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Figure 2.  A schematic model of the HA receptor  binding site indi- 
cating hydrogen  bonding of bound sialic acid. (9). 
the receptor. The floor is made of Tyr 98 and Trp 153, and 
Glu 190, Leu 194 project down from a short o~-helix which, 
together with His 183 and Thr 155, constitute the rear of 
the cleft. Residues 134-138 are on the right and 224-228 are 
on the left. Consider below the residue changes in mutant 
HAs that we have identified in this  study. 
IMUT4-V33:190  Glu --~ Asp, 226 Leu  -* Gin.  In H3 
subtype viruses,  190 Glu is a conserved negatively charged 
residue projecting down into the cleft and hydrogen bonded 
to sialic acid. The topographic relation of Glu 190 to Leu 
226, and their role in receptor function is evident from their 
molecular location. No laboratory variants have been reported 
for Glu  190 or Leu 226  but,  it is interesting to note that 
recent natural isolates of the H3 subtype have the same sub- 
stitutions, 190 Glu ~  Asp and 226 Leu -~ Gin (Dr. A. Hay, 
World Influenza Centre, National Institute for Medical Re- 
search, personal communication). This highlights the struc- 
tural constraints imposed on mutations within the conserved 
receptor-binding site,  and the possible significance of such 
changes in the selection of natural variant viruses with al- 
tered receptor specificity. 
A receptor-binding variant of X31, 226 Leu ~  Gln, selected 
in  the  presence  of horse  c~2-macroglobulin,  differs  from 
wild-type virus in its ability to agglutinate RBC containing 
sialyl c~2,3 linkages (12). The crystal structure of the variant 
HA (9) indicates that minimal changes have occurred in the 
receptor pocket so as to accommodate the additional hydrogen- 
bonding potential of Gln 226. 
VFX-33:155 Thr-'~ Ile.  In the crystal structure the aceta- 
midomethyl group of sialic acid is facing residue 155,  and 
the drift substitution 155 Thr ~  Tyr in natural isolates confers 
increased affinity for N-glycolyl sialic acid residues (14). Mu- 
tant VFX-33 also exhibits specificity for N-glycolyl sialic acid 
and agglutinates horse RBC, and it is interesting to note that 
the same 155 Thr ~  lie change has occurred in natural iso- 
lates of the H3N2 subtype (A/CAEN/83 or A/SOF/84; Dr. 
J. J.  Skehel,  personal communication). 
There are previous reports of influenza variant viruses with 
altered receptor-binding specificity that had been selected, in 
vitro with subneutralizing amounts of either polyclonal Ab 
(15) or a mixture of mAbs specific for several distinct anti- 
genic sites (16). Moreover, mAb-selected antigenic variants 
can exhibit different specificities for enzymatically or chemi- 
cally altered RBC (17). Daniels et al. (13) have described a 
mAb to X31 virus that failed to discriminate between nat- 
ural isolates of the H3 subtype and selected receptor-binding 
variants of X31 with substitutions at HA1 193 Ser --~ Asn, 
218 Gly ~  Glu,  226  Leu -~ Pro, or deletion of 224-230. 
With the exception of HA1 193, these changes do not abro- 
gate Ab recognition of mutant virus (in ELISA assays) and 
therefore qualify as receptor-binding mutants. 
A significant finding of this study is that constraints can 
be imposed on antigenic variation in influenza hemagglu- 
tinin, by a limited number of mutations in defined Ab rec- 
ognition sites, resulting in the selection of a receptor-binding 
variant virus (HA1 190 Glu -* Asp, 226 Leu ~  Gln). This 
had been the initial aim of Fazekas de St. Groth (15), some 
20 yr ago, namely to anticipate antigenic drift in influenza, 
by Ab selection, so as to produce a candidate vaccine strain. 
Since these same residue changes have been found in recent 
human H3 isolates,  this may indicate that there are similar 
constraints to further antigenic change within the human 
population. Our findings emphasize that the receptor-binding 
specificity (or affinity) of virus may be an important factor 
in immune evasion  of neutralizing Ab. 
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